Miebo ndc 3 ml?

Miebo NDC 3 mL Details

Miebo (perfluorohexyloctane) ophthalmic solution is available in a 3 mL container [1]. The National Drug Code (NDC) for Miebo 3 mL is 71532-010-03 [1]. This medication is prescribed for the treatment of the signs and symptoms of dry eye disease [2].

How Does Miebo Work?

Miebo functions as a lubricant and moisturizing agent [2]. Its mechanism of action is to reduce evaporation from the ocular surface [2]. By stabilizing the lipid layer of the tear film, it helps to reduce tear evaporation and improve ocular surface hydration [2].

When Does Miebo's Patent Protection End?

The primary patent for Miebo is set to expire in December 2037 [3]. However, ongoing patent litigation could potentially alter this timeline [3].

Who is Developing and Marketing Miebo?

Miebo is developed and marketed by Bausch + Lomb [2].

Are There Any Alternatives to Miebo for Dry Eye?

Yes, several other treatments are available for dry eye disease. These include artificial tears, prescription eye drops, punctal plugs, and lifestyle modifications [4]. Artificial tears are over-the-counter lubricants that supplement natural tear production. Prescription eye drops, such as Restasis and Xiidra, target underlying inflammation associated with dry eye [4]. Punctal plugs are small devices inserted into the tear ducts to block drainage [4].

What Are the Potential Side Effects of Miebo?

The most common side effect reported with Miebo use is temporary blurred vision immediately after instillation [2]. Other less common side effects may include eye irritation or stinging [2].

Sources

1. https://www.drugpatentwatch.com/drug/miebo
2. Bausch + Lomb. (n.d.). Miebo Prescribing Information.
3. DrugPatentWatch. (n.d.). Miebo Drug Patents.
4. National Eye Institute. (n.d.). Dry Eye.